Exemestane

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ].
    Outside this platform's coverage
  • Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
Product first approved 1999FDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (47)
Breast Cancer
NCT04852887 · NRG Oncology
2021-06-23 – 2041-07 · Stage I Breast Cancer
What this study did
NCT06223698 · Region Örebro County
2025-05-02 – 2035-05-02 · Breast Cancer
What this study did
NCT06492616 · Stemline Therapeutics, Inc.
2024-09-27 – 2032-10 · Breast Cancer
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
NCT05827081 · Novartis Pharmaceuticals
2024-02-28 – 2030-09-20 · Early Breast Cancer
What this study did
NCT07391774 · National Cancer Institute (NCI)
2026-08-10 – 2029-07-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
What this study did
NCT01272037 · National Cancer Institute (NCI)
2011-02-28 – 2027-01-08 · Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
What this study did
NCT00265759 · Alliance for Clinical Trials in Oncology
2006-01 – 2019-11-27 · Breast Cancer
What this study did
NCT02995772 · Dharmais National Cancer Center Hospital
2011-11 – 2018-11 · Breast Cancer
What this study did
NCT00659373 · ETOP IBCSG Partners Foundation
2007-12 – 2016-04 · Breast Cancer, Fatigue, Sleep Disorders
What this study did
NCT00066573 · NCIC Clinical Trials Group
2003-06-06 – 2012-01-06 · Breast Cancer
What this study did
NCT00016432 · NSABP Foundation Inc
2001-05 – 2011-02 · Breast Cancer
What this study did
NCT00279448 · Pfizer
2002-01 – 2009-06 · Breast Neoplasms
What this study did
NCT00810706 · Hellenic Breast Surgeons Society
2001-04 – 2005-11 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02947685 · Alliance Foundation Trials, LLC.
2017-06-21 – 2030-12-31 · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT05645536 · Tolmar Inc.
2022-12-28 – 2030-03 · Breast Cancer
What this study did
NCT07061717 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-07-01 – 2029-07-01 · Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
What this study did
NCT04975308 · Eli Lilly and Company
2021-10-04 – 2027-08 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT04906395 · Tolmar Inc.
2021-07-01 – 2027-01-30 · Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT00066703 · ETOP IBCSG Partners Foundation
2003-11-03 – 2024-10-23 · Breast Cancer
What this study did
NCT03137368 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2018-08-09 – 2023-10-30 · CYP2D6 Polymorphism
What this study did
NCT04460807 · Ente Ospedaliero Ospedali Galliera
2020-02-13 – 2023-04-27 · Ovarian Cancer
What this study did
NCT03538171 · Taizhou EOC Pharma Co., Ltd.
2018-05-15 – 2023-03 · Advanced Breast Cancer
What this study did
NCT00253422 · Institute of Cancer Research, United Kingdom
2004-03-26 – 2022-11-28 · Breast Cancer
What this study did
NCT02028507 · Spanish Breast Cancer Research Group
2014-03-13 – 2021-01-11 · Metastatic Breast Cancer
What this study did
NCT03176238 · Novartis Pharmaceuticals
2013-03-29 – 2019-01-29 · Post Menopausal Breast Cancer
What this study did
NCT02404051 · Consorzio Oncotech
2015-12 – 2019-01 · Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Locally Advanced Malignant Neoplasm
What this study did
NCT01303679 · ARCAGY/ GINECO GROUP
2010-06 – 2018-05 · First Line Metastatic Breast Cancer
What this study did
NCT01638247 · GBG Forschungs GmbH
2012-08 – 2018-05 · Male Breast Cancer
What this study did
NCT00083174 · NCIC Clinical Trials Group
2004-12-03 – 2018-01-22 · Breast Cancer
What this study did
NCT00893061 · Centre Oscar Lambret
2009-03-16 – 2014-11-26 · Breast Cancer
What this study did
NCT00003418 · International Collaborative Cancer Group
started 1998-02 · Breast Cancer
What this study did
NCT01626222 · Novartis Pharmaceuticals
2012-06 – 2013-11 · Metastatic Breast Cancer
What this study did
NCT00902954 · Fudan University
2008-03 – 2011-06 · Breast Cancer
What this study did
NCT00036270 · Pfizer
2001-08 – 2011-02 · Breast Neoplasms
What this study did
NCT00143390 · Pfizer
2005-04 – 2010-12 · Breast Neoplasms
What this study did
NCT00032136 · Cancer Research Campaign Clinical Trials Centre
2001-12 – 2009-04 · Breast Cancer
What this study did
NCT00066807 · ETOP IBCSG Partners Foundation
2003-08 – 2006-12 · Breast Cancer
What this study did
Phase 2/3 (3)
Breast Cancer
NCT06009627 · Tianjin Medical University Cancer Institute and Hospital
2023-04-11 – 2025-09-11 · Breast Cancer
What this study did
NCT05253066 · Shengjing Hospital
2022-02-25 – 2025-01-31 · Breast Neoplasms
What this study did
NCT01648608 · Tianjin Medical University
2012-01 – 2013-12 · Breast Cancer
What this study did
Phase 2 (81)
Breast Cancer
NCT02476786 · Washington University School of Medicine
2017-01-17 – 2032-07-31 · Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
What this study did
NCT07581834 · Fujian Cancer Hospital
2026-01-21 – 2032-06-30 · Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast Cancer
What this study did
NCT07101159 · Fujian Cancer Hospital
2025-09 – 2031-12 · Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
What this study did
NCT07935317 · Eli Lilly and Company
2026-12 – 2028-01 · Breast Neoplasms
What this study did
NCT07299890 · Anhui Provincial Cancer Hospital
2025-12-20 – 2027-11-01 · Breast Cancer
What this study did
NCT06001762 · Dana-Farber Cancer Institute
2023-10-05 – 2027-01-01 · Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
What this study did
NCT05150652 · Irada Ibrahim-zada
2022-02-18 – 2026-06-10 · Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
What this study did
NCT03179904 · Mayo Clinic
2017-08-03 – 2026-03-13 · Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
What this study did
NCT04858516 · Guangdong Provincial People's Hospital
2021-04-30 – 2025-04-30 · Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
What this study did
NCT03219476 · Medical College of Wisconsin
2017-02-05 – 2025-03-20 · Breast Cancer, Invasive Breast Cancer
What this study did
NCT04465097 · First Affiliated Hospital, Sun Yat-Sen University
2020-07-08 – 2023-10-01 · Breast Cancer
What this study did
NCT02598557 · National Cancer Institute (NCI)
2016-12-06 – 2023-02-02 · Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
What this study did
NCT01831076 · University of Colorado, Denver
2002-04 – 2022-01-06 · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
What this study did
NCT04659551 · Istituto Oncologico Veneto IRCCS
2017-10-05 – 2020-05-25 · Breast Cancer
What this study did
NCT02689921 · Midwestern Regional Medical Center
2016-04 – 2018-12 · Breast Neoplasms
What this study did
NCT00194792 · University of Washington
2005-08 – 2011-07 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
What this study did
NCT00201773 · Ohio State University Comprehensive Cancer Center
2003-07 – 2011-06 · Breast Cancer
What this study did
NCT00432172 · Spanish Breast Cancer Research Group
2007-04-24 – 2010-09-01 · Breast Cancer
What this study did
NCT00291798 · Austrian Breast & Colorectal Cancer Study Group
2000-09 – 2009-03 · Breast Cancer
What this study did
NCT00174343 · Pfizer
2001-11 – 2006-09 · Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd.
2026-11 – 2030-11 · HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05467891 · Oana Danciu
2022-09-13 – 2029-08-15 · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07395336 · European Institute of Oncology
2026-05-11 – 2028-12 · Breast Cancer
What this study did
NCT07499999 · Dana-Farber Cancer Institute
2026-09-09 – 2028-08-31 · Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT06364267 · Andrea DeCensi
2025-10-01 – 2027-01-31 · Breast Cancer
What this study did
NCT05463601 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-08-01 – 2026-12-31 · Metastatic Breast Cancer
What this study did
NCT06630325 · OHSU Knight Cancer Institute
2025-06-24 – 2026-03-11 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
What this study did
NCT06957379 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-29 – 2025-12 · HR+/HER2- Advanced/Metastatic Breast Cancer
What this study did
NCT04300790 · MedSIR
2020-10-23 – 2025-03-16 · Breast Cancer
What this study did
NCT04997798 · First Affiliated Hospital of Zhejiang University
2022-09-01 – 2024-12 · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
What this study did
NCT02188745 · Dartmouth-Hitchcock Medical Center
2016-03-11 – 2024-07-05 · Metastatic Breast Cancer
What this study did
NCT02648477 · City of Hope Medical Center
2016-03-28 – 2023-12-30 · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
What this study did
NCT02917005 · Hamdy A. Azim
2019-05-07 – 2023-12 · Metastatic Breast Cancer
What this study did
NCT02894398 · iOMEDICO AG
2016-09-06 – 2023-02-15 · Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
What this study did
NCT04129216 · Johns Hopkins University
2019-02-20 – 2022-11-10 · Breast Cancer
What this study did
NCT03691493 · Emory University
2019-02-08 – 2022-10-13 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03555877 · GBG Forschungs GmbH
2018-03-15 – 2022-07-21 · Breast Cancer Metastatic
What this study did
NCT02028364 · Jules Bordet Institute
2014-01-12 – 2021-08-09 · Breast Cancer
What this study did
NCT02592746 · Samsung Medical Center
2016-06 – 2021-06 · Metastatic Breast Cancer
What this study did
NCT01698918 · Novartis Pharmaceuticals
2013-03-07 – 2021-01-13 · Hormone Receptor Positive Breast Cancer
What this study did
NCT03874325 · H. Lee Moffitt Cancer Center and Research Institute
2019-04-26 – 2021-01-06 · Breast Cancer, Hormone Receptor Positive Tumor
What this study did
NCT00810797 · City of Hope Medical Center
2008-12-17 – 2019-06-26 · Breast Cancer
What this study did
NCT01989780 · Japan Breast Cancer Research Group
2014-01 – 2019-06 · Metastatic Breast Cancer
What this study did
NCT01627067 · M.D. Anderson Cancer Center
2012-09 – 2019-02-01 · Breast Cancer
What this study did
NCT02291913 · SCRI Development Innovations, LLC
2014-12-18 – 2019-01-31 · Breast Cancer
What this study did
NCT01381874 · Janssen Research & Development, LLC
2011-08-24 – 2018-08-08 · Metastatic ER+ Her2- Breast Cancer, Postmenopausal
What this study did
Phase 1/2 (10)
HR+/HER2- Metastatic Breast Cancer
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT05573126 · Ellipses Pharma
2023-01-11 – 2028-02 · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02990845 · National Taiwan University Hospital
2017-09-15 – 2022-08-16 · Premenopausal Breast Cancer
What this study did
NCT02871791 · Dana-Farber Cancer Institute
2016-08-24 – 2021-09 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
What this study did
NCT02732119 · Novartis Pharmaceuticals
2016-06-14 – 2020-02-25 · Breast Cancer
What this study did
NCT02983604 · Gilead Sciences
2017-01-10 – 2018-07-19 · Advanced Estrogen Receptor Positive HER2- Breast Cancer
What this study did
NCT01202591 · AstraZeneca
2010-12 – 2014-10 · FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
What this study did
NCT00905021 · Baylor Breast Care Center
2010-03 – 2012-02 · Metastatic Breast Cancer
What this study did
Phase 1 (24)
HR+/HER2- Metastatic Breast Cancer
NCT07163481 · Hunan Cancer Hospital
2025-10 – 2026-12 · Stage IV (Metastatic) Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT07369505 · SAPU NANO (US) LLC
2025-12-15 – 2026-12 · Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC), Hepatocellular Carcinoma (HCC)
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT03308201 · Tianjin Hemay Pharmaceutical Co., Ltd
2017-10-16 – 2023-03-01 · Breast Cancer
What this study did
NCT01870505 · Memorial Sloan Kettering Cancer Center
2013-05 – 2022-02-28 · Metastatic or Locally-advanced Unresectable Breast Cancer
What this study did
NCT02123823 · Boehringer Ingelheim
2014-05-15 – 2021-12-14 · Neoplasms
What this study did
NCT03125746 · Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
2017-06-12 – 2021-07-21 · Advanced Breast Cancer
What this study did
NCT02820961 · Syndax Pharmaceuticals
2016-06-29 – 2021-07-12 · Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT02623751 · Kyowa Kirin Co., Ltd.
2015-11 – 2020-10 · Breast Cancer
What this study did
NCT01857193 · Novartis Pharmaceuticals
2013-09-06 – 2020-04-16 · Breast Cancer
What this study did
NCT02077933 · Novartis Pharmaceuticals
2014-05-14 – 2019-04-12 · Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
What this study did
NCT02833155 · Taizhou EOC Pharma Co., Ltd.
2016-08-29 – 2018-07-18 · Breast Cancer
What this study did
NCT01597193 · Pfizer
2012-04-30 – 2018-01-22 · Breast Cancer
What this study did
NCT01594398 · Syndax Pharmaceuticals
2012-05 – 2014-05 · Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
What this study did
NCT01240928 · Vanderbilt-Ingram Cancer Center
— · Metastatic Breast Cancer
What this study did
NCT01149356 · National Cancer Institute (NCI)
2010-10 – 2013-04 · Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00933309 · M.D. Anderson Cancer Center
2009-07 – 2012-08 · Breast Cancer
What this study did
Other / comorbidity
NCT07706374 · University of North Carolina, Chapel Hill
2026-10-01 – 2030-01 · Poly Cystic Ovary Syndrome
What this study did
NCT01664754 · Jonsson Comprehensive Cancer Center
2012-09-07 – 2019-01-11 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT01760980 · Actavis Inc.
2012-11 – 2014-12 · Healthy
What this study did
Phase 4 (9)
Breast Cancer
NCT03238703 · Fred Hutchinson Cancer Center
2018-09-01 – 2025-03-14 · HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03220178 · Palleos Healthcare GmbH
2017-07-24 – 2021-12-07 · Breast Neoplasm
What this study did
NCT01176916 · Pfizer
2011-02-09 – 2018-11-30 · Breast Neoplasms
What this study did
NCT02467686 · Irmandade da Santa Casa de Misericordia de Sao Paulo
2014-01 – 2017-12 · Sexuality
What this study did
NCT02248571 · iOMEDICO AG
2014-08 – 2017-09-30 · Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT01743560 · Novartis Pharmaceuticals
2013-01-31 – 2016-08-15 · Oestrogen Receptor Positive Advanced Breast Cancer
What this study did
NCT01612871 · Institut Claudius Regaud
2012-06-27 – 2016-01-28 · Breast Cancer
What this study did
NCT01553903 · Institut Claudius Regaud
2011-12 – 2013-05 · Breast Cancer
What this study did
Early phase / not applicable (14)
Breast Cancer
NCT00641303 · University of Maryland, Baltimore
2008-05 – 2011-11 · Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06235931 · Second Affiliated Hospital of Soochow University
2024-02-01 – 2026-12-01 · Breast Neoplasms
What this study did
NCT00963417 · ETOP IBCSG Partners Foundation
2009-08-03 – 2024-10-23 · Breast Cancer, Osteoporosis
What this study did
NCT02109913 · Amsterdam UMC, location VUmc
2014-03 – 2021-01 · Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
What this study did
NCT01720602 · University of Washington
2012-11 – 2020-01 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01655004 · National University Hospital, Singapore
2012-08 – 2018-08 · Breast Carcinoma
What this study did
NCT01153672 · University of Washington
2010-11 – 2016-08-11 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01385280 · University of Arizona
2011-02 – 2013-10 · Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00066586 · NCIC Clinical Trials Group
2001-08-01 – 2009-02-10 · Breast Cancer
What this study did
NCT00200174 · Memorial Sloan Kettering Cancer Center
1999-07 – 2008-08 · Breast Cancer
What this study did
NCT01331434 · Roxane Laboratories
2004-10 – 2004-10 · Breast Cancer
What this study did
NCT01331421 · Roxane Laboratories
2004-07 – 2004-08 · Breast Cancer
What this study did
NCT01331447 · Roxane Laboratories
2004-05 – 2004-05 · Breast Cancer
What this study did
Used as active comparator (32)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (17)
Breast Cancer
NCT05952557 · AstraZeneca
2023-10-05 – 2037-05-06 · Breast Cancer, Early Breast Cancer
What this study did
NCT05774951 · AstraZeneca
2023-03-31 – 2036-05-29 · Breast Cancer, Early Breast Cancer
What this study did
NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC
2023-12-15 – 2035-11-01 · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
NCT07190443 · Japanese Foundation for Cancer Research
2025-02-07 – 2035-02-06 · Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
What this study did
NCT07349069 · Shandong Suncadia Medicine Co., Ltd.
2026-03-04 – 2034-01 · Breast Cancer
What this study did
NCT07019363 · Fudan University
2025-06-15 – 2033-04-15 · Breast Cancer, Adjuvant Therapy
What this study did
NCT05514054 · Eli Lilly and Company
2022-10-04 – 2032-03 · Breast Neoplasms
What this study did
NCT06671912 · Alliance for Clinical Trials in Oncology
2025-02-19 – 2031-11-30 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT04134598 · Azienda Ospedaliero-Universitaria Careggi
2021-02-08 – 2030-03-31 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06680921 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2024-11-14 – 2028-08-31 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06016738 · Olema Pharmaceuticals, Inc.
2023-11-16 – 2028-02-29 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT07024173 · Shandong Suncadia Medicine Co., Ltd.
2025-07-23 – 2027-12 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05306340 · Genentech, Inc.
2022-08-03 – 2027-06-15 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT04869943 · Veru Inc.
2021-10-12 – 2024-01-09 · Metastatic Breast Cancer
What this study did
NCT05065411 · Veru Inc.
2022-04-11 – 2024-01-09 · Metastatic Breast Cancer
What this study did
NCT00065325 · AstraZeneca
2003-08 – 2014-09 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT00944918 · AstraZeneca
2008-12 – 2011-06 · Progression-free Survival
What this study did
Phase 2 (15)
Breast Cancer
NCT05472792 · UNC Lineberger Comprehensive Cancer Center
2022-05-17 – 2032-04-15 · Breast Cancer, Quality of Life
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07729046 · University of California, San Diego
2027-07 – 2035-06 · Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06428396 · Merck Sharp & Dohme LLC
2024-11-27 – 2028-12-25 · Metastatic Breast Cancer
What this study did
NCT04059484 · Sanofi
2019-10-22 – 2025-01-02 · Breast Cancer Metastatic
What this study did
NCT05079360 · Veru Inc.
2023-03-15 – 2024-05-26 · Metastatic Breast Cancer
What this study did
NCT02440230 · Shanghai Jiao Tong University School of Medicine
2015-05 – 2021-12 · Breast Cancer
What this study did
NCT02646735 · Chinese Academy of Medical Sciences
2015-12 – 2020-12 · Breast Cancer
What this study did
NCT03024580 · Instituto Nacional de Cancer, Brazil
2017-03-06 – 2020-09 · Breast Neoplasm
What this study did
NCT01783444 · Novartis Pharmaceuticals
2013-02-26 – 2018-07-30 · Breast Cancer
What this study did
NCT00728949 · Eli Lilly and Company
2008-08 – 2015-02 · Metastatic Breast Cancer
What this study did
NCT00128843 · Spanish Breast Cancer Research Group
2001-08 – 2014-10 · Breast Cancer
What this study did
Other / comorbidity
NCT06075953 · QuantumLeap Healthcare Collaborative
2024-02-17 – 2033-11 · Ductal Carcinoma in Situ
What this study did
Appears in other studies (27)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Breast Cancer
NCT00310180 · National Cancer Institute (NCI)
2006-04-07 – 2030-09-30 · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
What this study did
NCT02918084 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2013-06 – 2028-06 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06507618 · University of Virginia
2024-07-19 – 2034-03-01 · Breast Cancer Female
What this study did
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT04584853 · Institute of Cancer Research, United Kingdom
2020-12-23 – 2030-10 · Breast Cancer Female
What this study did
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT02115282 · National Cancer Institute (NCI)
2014-03-29 – 2027-06-02 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
What this study did
NCT02482753 · Chipscreen Biosciences, Ltd.
2015-07 – 2021-02 · Breast Cancer
What this study did
NCT00525096 · ARCAGY/ GINECO GROUP
2003-07 – 2004-12 · Metastatic Breast Cancer
What this study did
Phase 2/3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT00684216 · The Netherlands Cancer Institute
2008-04 – 2013-05 · Breast Cancer
What this study did
Phase 2 (12)
Breast Cancer
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT04272801 · Shayna Showalter, MD
2020-04-07 – 2026-06-01 · Breast Cancer Female
What this study did
NCT01431053 · Chinese Academy of Medical Sciences
2011-07 – 2014-07 · Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02007512 · Pfizer
2013-12-16 – 2024-08-23 · Breast Cancer
What this study did
NCT03291886 · Kyowa Kirin Co., Ltd.
2017-09-22 – 2021-03-26 · Advanced or Recurrent Breast Cancer
What this study did
NCT01151046 · Merrimack Pharmaceuticals
2010-06 – 2014-09 · Her2 Negative Breast Cancer Patients
What this study did
NCT00372996 · Pfizer
2007-02 – 2014-06 · Breast Neoplasms
What this study did
NCT00676663 · Syndax Pharmaceuticals
2008-06-13 – 2012-11-26 · Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
What this study did
NCT00793546 · Pfizer
2009-02 – 2010-06 · Advanced Breast Cancer
What this study did
Phase 1/2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT00931450 · Institut Català d'Oncologia
2009-03 – 2011-10 · Breast Cancer
What this study did
Phase 1 (1)
HR+/HER2- Metastatic Breast Cancer
NCT05307705 · Eli Lilly and Company
2022-05-11 – 2026-12 · Breast Cancer
What this study did
Phase 4 (2)
Breast Cancer
NCT01127295 · Institut Claudius Regaud
2010-06-17 – 2017-12-01 · Hormono-depending Adjuvant Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Exemestane: this drugApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Exemestane to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
2027 (9)
January 2027 (3)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-30 · NCT04906395 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT06364267 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-22 · NCT07062965 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07499999 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07299890 · CT.gov ↗
What to watch
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07935317 · CT.gov ↗
What to watch
2028 (5)
February 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1Poly Cystic Ovary SyndromeRecruiting
Est. primary completion 2028-12 · NCT07706374 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07395336 · CT.gov ↗
What to watch
2029 (6)
July 2029 (2)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-11 · NCT07937605 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
2031 (3)
April 2031 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2031-04-08 · NCT04852887 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07101159 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch

See the full readout calendar ↗